GBGerold Bepler

Gerold Bepler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerold Bepler has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19

    by Ananda S. Prasad, Agnes Malysa, Gerold Bepler, Andrew Fribley, Bin Bao

    The pandemic of COVID-19 was caused by a novel coronavirus termed as SARS-CoV2 and is still ongoing with high morbidity and mortality rates in the whole world. The pathogenesis of COVID-19 is highly linked with over-active immune and inflammatory responses, leading to activated cytokine storm, which contribute to ARDS with worsen outcome. Currently, there is no effective therapeutic drug for the treatment of COVID-19. Zinc is known to act as an immune modulator, which plays an important role in immune defense system. Recently, zinc has been widely considered as an anti-inflammatory and anti-oxidant agent. Accumulating numbers of studies have revealed that zinc plays an important role in antiviral immunity in several viral infections. Several early clinical trials clearly indicate that zinc treatment remarkably decreased the severity of the upper respiratory infection of rhinovirus in humans. Currently, zinc has been used for the therapeutic intervention of COVID-19 in many different clinical trials. Several clinical studies reveal that zinc treatment using a combination of HCQ and zinc pronouncedly reduced symptom score and the rates of hospital admission and mortality in COVID-19 patients. These data support that zinc might act as an anti-viral agent in the addition to its anti-inflammatory and anti-oxidant properties for the adjuvant therapeutic intervention of COVID-19.


  • Open Access

    HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1

    by Niko Moses, Mu Zhang, Jheng-Yu Wu, Chen Hu, Shengyan Xiang, Xinran Geng, Yue Chen, Wenlong Bai, You-Wei Zhang, Gerold Bepler, et al.

    We have previously discovered that HDAC6 regulates the DNA damage response (DDR) via modulating the homeostasis of a DNA mismatch repair protein, MSH2, through HDAC6’s ubiquitin E3 ligase activity. Here, we have reported HDAC6’s second potential E3 ligase substrate, a critical cell cycle checkpoint protein, Chk1. We have found that HDAC6 and Chk1 directly interact, and that HDAC6 ubiquitinates Chk1 in vivo and in vitro. Specifically, HDAC6 interacts with Chk1 via the DAC1 domain, which contains its ubiquitin E3 ligase activity. During the cell cycle, Chk1 protein levels fluctuate, peaking at the G2 phase, subsequently resolving via the ubiquitin-proteasome pathway, and thereby allowing cells to progress to the M phase. However, in HDAC6 knockdown non-small cell lung cancer (NSCLC) cells, Chk1 is constitutively active and fails to resolve post-ionizing radiation (IR), and this enhanced Chk1 activity leads to preferential G2 arrest in HDAC6 knockdown cells accompanied by a reduction in colony formation capacity and viability. Depletion or pharmacological inhibition of Chk1 in HDAC6 knockdown cells reverses this radiosensitive phenotype, suggesting that the radiosensitivity of HDAC6 knockdown cells is dependent on increased Chk1 kinase activity. Overall, our results highlight a novel mechanism of Chk1 regulation at the post-translational level, and a possible strategy for sensitizing NSCLC to radiation via inhibiting HDAC6’s E3 ligase activity.


  • Open Access

    The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53

    by Chen Hu, Mu Zhang, Niko Moses, Cong-Li Hu, Lisa Polin, Wei Chen, Hyejeong Jang, Joshua Heyza, Agnes Malysa, Joseph A. Caruso, et al.

    : Ubiquitin-specific peptidase 10 (USP10) stabilizes both tumor suppressors and oncogenes in a context-dependent manner. However, the nature of USP10’s role in non-small cell lung cancer (NSCLC) remains unclear. By analyzing The Cancer Genome Atlas (TCGA) database, we have shown that high levels of USP10 are associated with poor overall survival in NSCLC with mutant p53, but not with wild-type p53. Consistently, genetic depletion or pharmacological inhibition of USP10 dramatically reduces the growth of lung cancer xenografts lacking wild-type p53 and sensitizes them to cisplatin. Mechanistically, USP10 interacts with, deubiquitinates, and stabilizes oncogenic protein histone deacetylase 6 (HDAC6). Furthermore, reintroducing either USP10 or HDAC6 into a USP10-knockdown NSCLC H1299 cell line with null-p53 renders cisplatin resistance. This result suggests the existence of a “USP10-HDAC6-cisplatin resistance” axis. Clinically, we have found a positive correlation between USP10 and HDAC6 expression in a cohort of NSCLC patient samples. Moreover, we have shown that high levels of USP10 mRNA correlate with poor overall survival in a cohort of advanced NSCLC patients who received platinum-based chemotherapy. Overall, our studies suggest that USP10 could be a potential biomarker for predicting patient response to platinum, and that targeting USP10 could sensitize lung cancer patients lacking wild-type p53 to platinum-based therapy.


  • Open Access

    HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1

    by Niko Moses, Mu Zhang, Jheng-Yu Wu, Chen Hu, Shengyan Xiang, Agnes Malysa, Hyejeong Jang, Wei Chen, Wenlong Bai, Gerold Bepler, et al.

    We previously discovered that HDAC6 regulates the DNA damage response via modulating the homeostasis of a DNA mismatch repair protein, MSH2, through HDAC6’s ubiquitin E3 ligase activity. Here, we have reported HDAC6’s second E3 ligase substrate, a critical cell cycle checkpoint protein, Chk1. We have found that HDAC6 and Chk1 directly interact, and that HDAC6 ubiquitinates Chk1 in vivo . Typical Chk1 protein levels fluctuate, peaking at G2 and subsequently resolving via the ubiquitin-proteasome pathway. However, in HDAC6 knockdown cells, Chk1 is constitutively active and fails to resolve post-ionizing radiation (IR), leading to increased radiation sensitivity. Upon IR treatment, a greater proportion of HDAC6 knockdown cells accumulated at G2/M phase when compared with control cells. Depletion or inhibition of Chk1 in HDAC6 knockdown cells renders those cells radiosensitive, suggesting that persistently high level of Chk1 could lead cells to arrest at G2/M phase and eventually, apoptosis. Clinically, we found that high levels of phosphorylated Chk1 (p-Ser317) are associated with a better overall survival in a cohort of non-small cell lung cancer (NSCLC) patients, suggesting a link between active Chk1 and lung cancer development. Overall, our results highlight a novel mechanism of Chk1 regulation at the protein level, and a possible strategy for sensitizing NSCLC to radiation via inhibiting the activity of HDAC6’s E3 ligase.


  • Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer

    by Joshua R. Heyza, Wen Lei, Donovan Watza, Hao Zhang, Wei Chen, Jessica B. Back, Ann G. Schwartz, Gerold Bepler, Steve M. Patrick

    Purpose:ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor specimens, and has been investigated as a predictive biomarker for efficacy of platinum-based chemotherapy. The failure of clinical trials utilizing ERCC1 expression to predict response to platinum-based chemotherapy suggests additional mechanisms underlying the basic biology of ERCC1 in the response to interstrand crosslinks (ICLs) remain unknown. We aimed to characterize a panel of ERCC1 knockout (D) cell lines where we identified a synthetic viable phenotype in response to ICLs with ERCC1 deficiency. Experimental Design:We utilized the CRISPR-Cas9 system to create a panel of ERCC1D lung cancer cell lines which we characterized. Results:We observe that loss of ERCC1 hypersensitizes cells to cisplatin when wildtype (WT) p53 is retained, while there is only modest sensitivity in cell lines that are p53mutant/null. Additionally, when p53 is disrupted by CRISPR-Cas9 (p53*) in ERCC1D/p53WT cells, there is reduced apoptosis and increased viability after platinum treatment. These results were recapitulated in two patient data sets utilizing p53 mutation analysis and ERCC1 expression to assess Overall Survival. We also show that kinetics of ICL- repair (ICL-R) differ between ERCC1D/p53WT and ERCC1D/p53* cells. Finally, we provide evidence that cisplatin tolerance in the context of ERCC1 deficiency relies on DNA-PKcs and BRCA1 function. Conclusions:Our findings implicate p53 as a potential confounding variable in clinical assessments of ERCC1 as a platinum biomarker via promoting an environment in which error-prone mechanisms of ICL- repair may be able to partially compensate for loss of ERCC1.


  • Open Access

    Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor

    by Mugdha Patki, Thomas McFall, Rayna Rosati, Yanfang Huang, Agnes Malysa, Lisa Polin, Abigail Fielder, Mike R. Wilson, Fulvio Lonardo, Jessica Back, et al.

    Dexamethasone (Dex), co-administered to lung adenocarcinoma patients with pemetrexed chemotherapy, protects against pemetrexed cytotoxicity by inducing reversible G1 arrest, reflected by the effect of Dex on FLT-PET images of patient tumors. However, perioperative Dex treatment increases survival but the mechanism is unknown. In cells with glucocorticoid receptor-α (GR) expression corresponding to higher clinical tumor levels, Dex-induced growth arrest was followed by marked cell expansion, beta-galactosidase expression and Ki67 negativity, despite variable p53 and K-RAS status. Dex induced a transient early surge in p21Cip1. However, a progressive, irreversible loss of clonogenic growth, whose time of onset was dependent on GR level and Dex dose, was independent of p21Cip1and caused by gradual accumulation of p27Kip1 due to transcriptional activation of p27Kip1 by Dex. This effect was independent of canonical pathways of senescence or p27Kip1 regulation. The in vitro observations were reflected by growth suppression and P27Kip1 induction in GR-overexpressing tumor xenografts compared with isogenic low-GR tumors. Extended Dex treatment induces irreversible cell cycle blockade and a senescence phenotype through chronic activation of the p27Kip1 gene in GR overexpressing lung tumor cell populations and hence could improve outcome of surgery/pemetrexed chemotherapy and sensitize tumors to immunotherapy.


  • Discoidin Domain Receptors in Lung Cancer

    by Yingtao Zhang, Agnes Malysa, Gerold Bepler

  • Mutational load in tumors of African-American non-small cell lung cancer (NSCLC) patients.

    by Ann G. Schwartz, Greg Dyson, Manish K. Thakur, Chrissy Lusk, Angie Wenzlaff, Sneh Lata, Susan Land, Gerold Bepler, Shirish M. Gadgeel

    8533 Background: Lung cancer is more common in African Americans (AA) and is associated with worse prognosis. Mutational load has been identified as a possible predictive marker for clinical benefit from anti-PD-1 drugs in NSCLC patients by Rizvi, et al (Science 2015), where the median number of non-synonymous mutations was 200. We assessed mutational load in tumors of AA patients and correlated it with clinical and demographic characteristics. Methods: Whole exome sequencing of both normal and tumor DNA utilizing the Illumina HiSeq 2500 instrument and the Illumina Exome Enrichment kit in a 12plex design was conducted on tumor tissues of 48 AA patients. Read mapping was done using Novoalign; variants were called using GATK and annotated using SnpEff. Variants included here were covered at a minimum depth of 50x in both normal and tumor samples. Results: The median age at diagnosis was 60 years; 54% were males, 94% were former or current smokers, 56% were stage I, 17% were stage II, 21% were stage III and 6% were stage IV. 71% of cases had a diagnosis of COPD. The median number of exonic mutations was 736 (range of 3–2249), while the median number of non-synonymous mutations was 340 (range of 0-947). Nonsynonymous mutational load (high vs. low, dichotomized at the median) was not associated with COPD status, after adjustment for age, pack years, family history of lung cancer and stage. However, stage was associated with nonsynonymous mutational load; specifically, the covariate-adjusted odds of a high mutational load for those diagnosed with later stage cancer (III/IV) were almost six times the odds of a high mutational load among those diagnosed with earlier stage cancer (I/II) (OR (95%CI) = 5.98 (1.42, 32.75), p = 0.022). Conclusions: Mutational load in tumors of AA NSCLC patients is higher than published data. Sources of variation may be attributable to both technical (calling algorithms, quality filters) and biological/clinical (race, stage) factors. Mutational load was associated with stage at diagnosis. Additional exome sequencing efforts are underway to evaluate mutational load by treatment response and driver mutation status, and to evaluate associations with outcome.

  • Open Access

    Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine

    by Xiaohong Mary Zhang, Navnath Gavande, Prahlad Parajuli, Gerold Bepler

    Lung cancer is the leading cause of cancer death among both men and women in the United States. Because lung cancer is genetically heterogeneous, tailored therapy alone or in combination with chemotherapy would increase patient overall survival as compared with the one-size-fits-all chemotherapy.